IOVA

Iovance Biotherapeutics, Inc. Common Stock

8.04

USD

+0.30

+3.88%

Nov 06, 15:59 UTC -5

Closed

Pre-Market

8.00

-0.04

-0.56%

Iovance Biotherapeutics, Inc. Common Stock (IOVA) Earnings

IOVA Earnings Reports

Positive Surprise Ratio

IOVA beat 22 of 44 last estimates.

50%

Next Report

Date of Next Report

Feb 22, 2027

Estimate for Q4 26 (Revenue/ EPS)

$131.43M

-$0.08

Implied change from Q3 26 (Revenue/ EPS)

+8.20%

+60.00%

Implied change from Q4 25 (Revenue/ EPS)

+51.47%

-55.56%

Iovance Biotherapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, IOVA reported earnings of -0.05 USD per share (EPS) for Q3 26, beating the estimate of -0.08 USD, resulting in a 42.59% surprise. Revenue reached 121.47 million, compared to an expected 118.30 million, with a 2.68% difference. The market reacted with a -11.03% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.08 USD, with revenue projected to reach 131.43 million USD, implying an increase of 60.00% EPS, and increase of 8.20% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Bio-Techne Corp.

Report Date

Nov 06, 2026 For Q1 27

Estimate

$0.44

Actual

$0.44

Surprise

-1.96%

Immunocore Holdings plc - ADR

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.13

Actual

-$0.28

Surprise

-104.08%

Entera Bio Ltd. Ordinary Shares

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.06

Actual

-$0.11

Surprise

-58.50%

Vogenx Inc Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.47

Surprise

-187.99%

Agenus Inc.

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.27

Actual

$0.02

Surprise

+107.26%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

-$0.02

Surprise

-132.68%

Aligos Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$2.21

Actual

-$2.09

Surprise

+5.58%

CervoMed Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.49

Actual

-$0.39

Surprise

+21.97%

Creative Medical Technology Holdings, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.40

Surprise

-63.40%

FAQ

What were Iovance Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Iovance Biotherapeutics, Inc. Common Stock reported EPS of -$0.05, beating estimates by 42.59%, and revenue of $121.47M, 2.68% above expectations.

How did the market react to Iovance Biotherapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved down -11.03%, changed from $8.70 before the earnings release to $7.74 the day after.

When is Iovance Biotherapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 22, 2027.

What are the forecasts for Iovance Biotherapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Iovance Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $131.43M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.